zunveyl
zunveyl: sourced relationships with 1 company · 1 clinical trial tracked · 1 FDA decision.
zunveyl evidence translation
What we can confirm
1 FDA record · 1 tracked trial
What it means
What to watch
Prepared research question
How could zunveyl → ACOG affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Alpha Cognition Inc. (ACOG) | Phase 4 |
Clinical Trial Registry Records (1)
RESOLVE: A Phase 4, Open-label Study to Assess the Effect of Zunveyl on Safety and Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Adults With Mild to Moderate Alzheimer's Disease
Primary endpoint: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with zunveyl?
zunveyl has dated SEC/FDA relationship records for Alpha Cognition Inc..
How many clinical trials involve zunveyl?
BioSniper tracks 1 clinical trial involving zunveyl.
What is zunveyl's latest FDA decision?
The most recent tracked FDA decision for zunveyl is Approval for 1 INDICATIONS AND USAGE ZUNVEYL is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults ( 1 ), dated July 26, 2024.